Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
February 01, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
January 06, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
October 20, 2022 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology

SAN DIEGO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced...
September 29, 2022 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer

SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...
September 13, 2022 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces the Appointment of Seasoned Biotech Leader Athena Countouriotis, M.D., as the Chairperson of the Board of Directors

SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...
January 06, 2022 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Scientific Advisory Board

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...
November 15, 2021 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO

Three SH2 domain inhibitor programs targeting STAT3, STAT6 and an undisclosed non-STAT target are underwayNancy Whiting, Pharm.D. -- an industry veteran and one of Fierce Pharma’s Fiercest Women in...